The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2022

Filed:

Sep. 09, 2020
Applicant:

Iteos Belgium SA, Gosselies, BE;

Inventors:

Stefano Crosignani, Nivelles, BE;

Erica Joke Katelijne Heleen Houthuys, Petit-Enghien, BE;

Reece Gerrad Marillier, Chaumont-Gistoux, BE;

Chiara Martinoli, Milan, IT;

Oliver De Henau, Watermaele-Boitsfort, BE;

Gregory Driessens, Ottignies, BE;

Assignee:

iTeos Belgium SA, Gosselies, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61P 35/00 (2006.01); A61K 31/5377 (2006.01); A61K 33/243 (2019.01); A61K 9/48 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/5377 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01);
Abstract

The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-α-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.


Find Patent Forward Citations

Loading…